Scandion Oncology: Supplement to previously published press release regarding the outcome of Scandion Oncology’s rights issue
The supplement refers to issue costs. As Scandion Oncology A/S ("Scandion" or the "Company") announced in the press release of 15 December 2020 (released at 08:49:27), the Company receives approximately SEK 236 million before issue costs from its rights issue. The issue costs amount to approximately SEK 36 million, which has been stated in the prospectus published by the Company on 24 November 2020. Hence, the Company receives net proceeds of approximately SEK 200 million from its rights issue. For further information, please contact: Bo Rode Hansen, CEO Phone: +45 38 10 20 17